Neurocognitive Impairment in Patients With COVID-19 (NCoV)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04359914|
Recruitment Status : Recruiting
First Posted : April 24, 2020
Last Update Posted : April 24, 2020
Delirium and acute neurocognitive impairment are increasingly observed in adult and pediatric patients with COVID-19. Prospective clinical studies combining clinical and laboratory examinations including specific biomarkers of neuroaxonal injury were not performed for COVID-19. The value of biomarkers of neuroaxonal injury was proven in preliminary studies. These biomarkers could thus contribute to the systematic detection of neurocognitive impairment in patients with COVID-19. Due to worldwide increasing numbers of hospitalized patients with COVID-19, biomarkers of neuroaxonal injury are highly valuable to detect and monitor cognitive impairment, especially with regard to limited resources available to perform time-consuming brain imaging.
Biomarkers of neuroaxonal injury are therefore not only of great interest to detect neurocognitive impairment but also to quantify the severity of brain injury in patients with COVID-19.
|Condition or disease|
|Critical Illness COVID-19 Central Nervous System Injury Delirium Encephalopathy|
This is a multicenter observational study evaluating the incidence and severity of neurocognitive impairment in adult and pediatric patients with COVID-19. All study participants will be assessed by clinical and neurological examination as well as comprehensive laboratory tests using biomarkers of neuroaxonal injury at study day 1 (day of study inclusion), day 3, day 7 and day of hospital discharge. A panel of biomarkers (among others NSE, S100B and neurofilament proteins) will be measured. Clinical assessment will be performed using validated delirium tests (among others CAM-ICU, ICDSC) and scales to assess the neurocognitive performance of study participants before and three months after study inclusion (among others Short Blessed Test).
A group of patients with a comparable severity of disease but without the detection of SARS-Cov-2 will serve as control group and will undergo the same clinical and laboratory examinations.
We hypothesize, that:
- patients with COVID-19 are more likely to develop delirium and neurocognitive impairment than patients without COVID-19
- patients with a preexisting neurocognitive deficit are more vulnerable to neurocognitive impairment in the course of COVID-19 than patients without a preexisting neurocognitive deficit
- Specific biomarkers of neuroaxonal injury correlate with the clinical severity of acute neurocognitive impairment and can predict the 3-month neurocognitive outcome of patients with COVID-19
|Study Type :||Observational|
|Estimated Enrollment :||80 participants|
|Official Title:||Biomarker-guided Assessment of Neurocognitive Impairment in Patients With COVID-19 - a Multicenter Case-control Study|
|Actual Study Start Date :||April 15, 2020|
|Estimated Primary Completion Date :||December 31, 2020|
|Estimated Study Completion Date :||April 1, 2021|
- Incidence of delirium/neurocognitive impairment in adult and pediatric patients with COVID-19 compared to patients without COVID-19 [ Time Frame: Day 90 ]Assessment of neurocognitive impairment using validated tools
- Change in neuroaxonal injury biomarker levels in patients with COVID-19 compared to patients without COVID-19 [ Time Frame: Change from baseline biomarker levels at day 28 ]Measurement of biomarker levels (e.g. NSE, S100B, neurofilament proteins) derived from blood samples
- Neurocognitive 3-months outcome in patients with COVID-19 compared to patients without COVID-19 [ Time Frame: Day 90 ]Assessment of the neurocognitive performance of patients using validated tests (e.g. Short Blessed Test)
- Neurocognitive 3-months outcome in patients with COVID-19 compared to patients without COVID-19 [ Time Frame: Change from baseline IQCODE results at day 90 ]Assessment of the change in the neurocognitive performance of patients using validated tests (e.g. IQCODE)
- Quality of life in patients with COVID-19 compared to patients without COVID-19 after hospital discharge [ Time Frame: Day 90 ]Assessment of the overall quality of life using validated tests [e.g. Modified Rankin Scale with a range from 0 (no symptoms) to 6 (dead)]
- Length of hospital stay in patients with COVID-19 compared to patients without COVID-19 [ Time Frame: 1 year ]Cumulative days in hospital
- 90-day survival in patients with COVID-19 compared to patients without COVID-19 [ Time Frame: Day 90 ]Survival after 90 days
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04359914
|Contact: Johannes Ehler, MDemail@example.com|
|Contact: Gerd Klinkmann, MD||+49381494146469||Gerd.Klinkmann@med.uni-rostock.de|
|Department of Anesthesiology and Intensive Care Medicine, University Medical Center Rostock||Recruiting|
|Rostock, Mecklenburg-Vorpommern, Germany, D-18057|
|Contact: Johannes Ehler, MD +49381494146467 firstname.lastname@example.org|
|Principal Investigator:||Johannes Ehler, MD||University of Rostock|